Synthesis and cytotoxic activity of conjugates of muramyl and normuramyl dipeptides with batracylin derivatives

Journal of Medicinal Chemistry

Volumn 46, Issue 6, 2003, Pages 978-986

  Dzierzbicka, Krystyna ^a   Trzonkowski, Piotr ^b   Sewerynek, Przemysław ^b   Myśliwski, Andrzej ^b  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BATRACYLIN; BATRACYLIN DERIVATIVE; MURAMYL DIPEPTIDE DERIVATIVE; N (1 O BENZYL N ACETYLMURAMYLVALYL DEXTRO GAMMA ISOGLUTAMINYL)BATRACYCLIN; N (1 O BENZYL N ACETYLNORMURAMYLALANYL DEXTRO GAMMA ISOGLUTAMINYL)BATRACYLIN; NORMURAMYL DIPEPTIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANIMALS; ANTINEOPLASTIC AGENTS; CRICETINAE; DIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; QUINAZOLINES; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037435066     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021067v     Document Type: Article

References (33)

1. Adam, A.; Lederer, E. Muramylpeptides: immunomodulators, sleep factors and vitamins. Med. Res. 1984, 4, 111-152.
2. Baschang, G. Muramylpeptides and lipopeptides: studies towards immunostimulants. Tetrahedron 1989, 45, 6331-6360.
3. Dzierzbicka, K.; Gozdowska, M.; Kołodziejczyk, A. M. Influence of immunomodulators of the type MDP on secretion and activity of cytokines. Postepy Biochem. 1998, 44 (3), 216-219.
4. Dzierzbicka, K.; Kołodziejczyk, A. M.; Wysocka-Skrzela, B.; Myśliwski, A.; Sosnowska, D. Synthesis and antitumor activity of conjugates of muramyldipeptides, normuramyldipeptide, and desmuramyldipeptides with acridine/acridone derivatives. J. Med. Chem. 2001, 44, 3606-3614.
5. Plowman, J.; Paull, K. D.; Atassi, G.; Harrison, S. D.; Dykes, D. J.; Kabbe, H. J.; Narayanan, V. L.; Yoder, O. C. Preclinical antitumor activity of batracylin (NSC 320846). Invest. New Drugs 1988, 6, 147-153.
6. Waud, W. R.; Harrison, S. D.; Gilbert, K. S.; Laster, W. R.; Griswold, D. P. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia. Cancer Chemother. Pharmacol. 1991, 27, 456-463.
7. Mucci-LoRusso, P.; Polin, L.; Bissery, M. C.; Valeriote, F.; Plowman, J.; Luk, G. D.; Corbett, T. H. Activity of batracylin (NSC 320846) against solid tumors of mice. Invest. New Drugs 1989, 7, 295-306.
8. Stevens, G. J.; Meegalla, S. K.; Makhey, D.; LaVoie, E. J.; McQueen, Ch. A. Genotoxicity of batracylin and several structural analogs. Proc. Am. Assoc. Cancer Res. 1993, 34, 158.
9. Stevens, G. J.; McQueen, Ch. A. Species variation in the genotoxicity of batracylin. Toxicol. Appl. Pharmacol. 1994, 126, 39-44.
10. El-Hawari, M.; Stoltz, M. L.; Pallas, F. Species differences in the toxic responses to batracylin (NSC 320846). Proc. Am. Assoc. Cancer Res. 1989, 30, 626.
11. Ames, M. M.; Mathiesen, D. A.; Reid, J. M. Differences in N-acetylation of the experimental antitumor agent batracylin in the mouse and the rat. Invest. New Drugs 1991, 9, 219-225.
12. Stevens, G. J.; LaVoie, E. J.; McQueen, Ch. A. The role of acetylation in the mutagenicity of the antitumor agent, batracylin. Carcinogenesis 1996, 17, 115-119.
13. Kabbe, H. J. Heterocycles from diamines and diacyl compounds. Justus Liebigs Ann. Chem. 1978, 398-404.
14. Luo, Y.; Ren, Y. F.; Chou, T. Ch.; Chen, A. Y.; Yu, Ch.; Liu, L. F.; Cheng, C. C. A structure-activity relationship study of batracylin analogues. Pharm. Res. 1993, 10 (6), 918-923.
15. Meegalla, S. K.; Stevens, G. J.; McQueen, Ch. A.; Chen, A. Y.; Yu, Ch.; Liu, L. F.; Barrows, L. R.; LaVoie, E. J. Synthesis and pharmacological evaluation of isoindolo [1,2-b] quinazolinone and isoindolo [2,1a] benzimidazole derivatives related to the antitumor agent. J. Med. Chem. 1994, 37, 3434-3439.
16. Roservear, J.; Wilshire, F. K. A comparison of the reactions of some ethyl N-arylcarbamates with those of the corresponding acetanilides. II Amidomethylation with N-hydroxymethylphthalimide. Aust. J. Chem. 1990, 43, 339-353.
17. Stella, V.; Al-Razzak, L. A.; Kabbe, H. J. U.S. Patent 4,980,343, 1990.
18. Lerchen, H. G.; Piel, N.; Lorentzen, J. P.; Antonicek, H. P.; Kabbe, H. J. Fucose-marked batracylin glycopeptide conjugates as antitumor agents. European Patent Office No. 0 501 250 Al, 1992; Chem. Abstr. 1993, 118, 60133k.
19. Lerchen, H. G.; Von Dem Bruch, K.; Petersen, U.; Baum-Gartem, J.; Piel, N.; Antonicek, H. P.; Weichel, W.; Sperzel, M.; Bremm, K.; Dieter, K. Preparation of carbohydrate-modified cytostatic agents. Patent No. PCT/EP96/01279, 1996; Chem. Abstr. 1997, 126, 31574q.
20. Dzierzbicka, K.; Kołodziejczyk, A. M.; Wysocka-Skrzela, B.; Kołodziejczyk, A. S. Synthesis of muramyl dipeptide conjugated with acridine derivatives, showing anti-HIV-1 and anticancer activity. Pol. J. Chem. 1994, 68, 37-45.
21. Gozdowska, M.; Dzierzbicka, K.; Wysocka-Skrzela, B.; Kołodziejczyk, A. M. Synthesis and in vitro anticancer activity of conjugates of MDP with amino-acridine/acridone derivatives. Pol. J. Chem. 1997, 71, 767-773.
22. Dzierzbicka, K.; Gozdowska, M.; Wysocka-Skrzela, B.; Kołodziejczyk, A. M. Synthesis and anticancer activites of new MDP conjugates with amino-acridine/acridone derivatives. Acta Pol. Pharm. 1999, 56, 20-24.
23. Sosnowska, D.; Myśliwski, A.; Dzierzbicka, K.; Kołodziejczyk, A. The in vitro effect of new muramyl peptide derivatives on cytotoxic activity of NK (Natural Killer) cells from hamsters bearing Ab Bomirski melanoma. Biotherapy 1997, 10, 161-168.
24. Lefrancier, P.; Choay, J.; Derrieu, M.; Lederman, I. Synthesis of N-acetylmuramyl-L-alanyl-D-isoglutamine, an adjuvant of the immune response and some N-acetylmuramyl peptide analogs. Int. J. Pept. Protein Res. 1977, 9, 249-257.
25. Gozdowska, M. Ph.D. Thesis, Gdansk University of Technology, Gdansk, Poland, 1998.
26. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
27. Grever, M. R.; Schepartz, S. A.; Chabner, B. A. The National Cancer Institute: Cancer Drug Discovery and Development Program. Sernin. Oncol. 1992, 19, 622-638.
28. Information from NCI, Bethesda MD.
29. Pfeiffer, F. R.; Case, F. H. The preparation of some pyrido and pyridyl derivatives ofphenazine and quinoxaline. J. Org. Chem. 1966, 31, 3384-3390.
30. Bomirski, A.; Slominski, A.; Bigda, J. The natural history of a family of transplantable melanomas in hamsters. Cancer Metastasis Rev. 1988, 7, 95-118.
31. Slominski, A.; Paus, R. Bomirski melanoma: a versatile and powerful model of pigment cell and melanoma research. Int. J. Oncol. 1993, 2, 221-228.
32. Giffney, C. J.; O'Connor, Ch. J. Spectrophotometric determination of basicity constants. Part II. Acetanilides. J. Chem. Soc., Perkin Trans. 2 1975, 706-712.
33. Schiff, H.; Ostrogovich, A. Uramide, urethane und oxamathane der p- und m-phenylendiamine. Justus Liebigs Ann. Chem. 1896, 293, 371-388.